Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
dry eye disease
Biotech
Stuart sees dry eye disease drug fail ph. 3 study, plans another
Stuart Therapeutics’ dry eye disease drug has failed to demonstrate it can increase tear production in a phase 3 test.
James Waldron
Jun 24, 2025 9:26am
Aldeyra posts hit, miss for dry eye drug, plans FDA filing
May 6, 2025 7:05am
Aldeyra’s dry eye drug suffers second FDA rejection
Apr 3, 2025 8:46am
Bausch + Lomb pens $485M-plus biobucks pact with City Tx
Jan 10, 2025 6:37am
Aldeyra preps for FDA refiling as dry eye drug hits ph. 3 goal
Aug 8, 2024 10:48am
Oculis sees promise in dry eye disease subgroup, plans phase 3
Jun 10, 2024 7:20am
